GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bayer AG (OTCPK:BAYRY) » Definitions » Institutional Ownership

Bayer AG (Bayer AG) Institutional Ownership : 0.44% (As of Apr. 27, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Bayer AG Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Bayer AG's institutional ownership is 0.44%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Bayer AG's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Bayer AG's Float Percentage Of Total Shares Outstanding is 0.00%.


Bayer AG Institutional Ownership Historical Data

The historical data trend for Bayer AG's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bayer AG Institutional Ownership Chart

Bayer AG Historical Data

The historical data trend for Bayer AG can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 0.37 0.36 0.38 0.40 0.39 0.38 0.38 0.39 0.39 0.44

Bayer AG Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Bayer AG (Bayer AG) Business Description

Address
Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.